Dermapharm acquires C³ Group

Martius advises Dermapharm Holding SE on the acquisition of C³ Cannabinoid Compound Company GmbH (C³ Group)

As the market leader for dronabinol in Germany and Austria, the C³ Group develops, produces and markets natural and synthetic cannabinoids In addition to C³ Cannabinoid Compound Company GmbH, the C³ Group includes the German subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, and THC Pharm GmbH The Health Concept, based in Frankfurt am Main, as well as Spectrum Therapeutics Austria GmbH, based in Vienna, Austria.

Martius regularly advises Dermapharm on its acquisitions and investments in Germany, Austria and abroad.


MARTIUS advised Dermapharm:

  • Dr. Philipp Kopp (Partner, M&A/Private Equity)

Dermapharm was also advised on legal matters by Schindler Rechtsanwälte (Vienna) and on antitrust matters by Buntscheck Rechtsanwälte (Munich).